Synaffix BV

Catch Diana Čekatauskaitė in Rotterdam next week as she presents at Innovation for Health 2025. See the details of Diana's presentation below and be sure to reach out to learn more about our cutting-edge clinical stage ADC platform technology. 📖 Synaffix Technology Toolbox: One-Stop Shop for Best-in-Class Antibody Conjugates 📅 Thursday, 3 April 2025 🕰️ 12:00 - 12:45 CEST #ADCs #bispecifics #innovation #drugdevelopment

SOTIO Biotech has announced it will be exercising its option with Synaffix BV to develop two bispecific antibody-drug conjugate (ADC) programs.   The bispecific antibody candidates were identified by SOTIO’s research team and will now be developed under SOTIO’s license and option agreement with Synaffix, which enables SOTIO to combine its proprietary antibodies with Synaffix’s GlycoConnect®, HydraSpace®, and potent linker-payload platforms to research, develop, manufacture, and commercialize ADC products.   Peter Van de Sande, Head of Synaffix, commented: “We are pleased that SOTIO, recognizing the versatility and robustness of our clinically validated platform, has chosen to expand its use of our ADC technology to two additional targets. Bispecific ADCs are a key part of our offering, and our technology is primed to support this next stage of innovation in targeted cancer therapeutics. We look forward to seeing these promising candidates advance toward the clinic.”   #ADCs #oncology #drugdevelopment #biotech

Tomorrow marks #IWD2025, and at Synaffix BV we are proud to support such an important initiative. International Women's Day serves as a reminder to highlight and celebrate women's achievements in all facets of life, personal and professional, while raising awareness of discrimination and promoting gender equality. Join us on this day as we #AccelerateAction and strive for a world that is diverse, equitable, and inclusive. Visit the website below to find out more.

Catch Synaffix BV B.V. Head of R&D Floris van Delft along with other members of the team in London next week for the 15th Annual #WorldADC 3rd- 6th March 2025. In his presentation on Wednesday at 10am, Floris will be outlining how Synaffix’s GlycoConnect® and HydraSpace® technologies enable ADCs with best-in-class therapeutic potential. The presentation will also detail technology expansion towards bispecific (bYIok®) and dual warhead ADCs with compelling in vivo data, alongside unprecedented mRNA exon skipping and dystrophin restoration in preclinical mouse model for Duchenne muscular dystrophy. Get in touch to arrange a meeting and learn more about how our clinical-stage platform technology can enhance your antibody into a best-in-class ADC or bispecific. We hope to see you there! #WorldADC #ADCs #bispecifics

Today marks #WorldCancerDay, which Synaffix BV is proud to support. This year’s campaign is defined by the slogan #UnitedbyUnique aiming to highlight the importance of the people at the centre of #cancercare, keeping their stories at the heart of the conversation. Over 35 million new cancer cases are predicted in 2050, and it is our mission to use our innovative technology to aid the development of best-in-class targeted cancer therapeutics.* With our industry-leading #ADC platform, we strive to advance targeted cancer therapies and transform #bispecific offerings. #adcs #oncology Source: Union for International Cancer Control (UICC)

Synaffix BV today announces it has signed a licensing deal with Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group. Under the agreement, MTPC gains access to Synaffix's GlycoConnect™, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement during the development of a single ADC program. For more information, see the full press release linked in the comments below. #ADCs #oncology #drugdevelopment #biotech

Synaffix BV today announces it has entered into an exclusive #ADC license agreement with Boehringer Ingelheim worth over $1.3 billion. Under the terms of the agreement, Synaffix will provide access to its proprietary ADC technologies for an agreed but undisclosed number of targets. The first target was nominated at signature, with additional targets to be nominated within a predefined timeframe. On top of the initial deal value, Synaffix is also eligible to receive tiered royalties on net sales. For more information, see the full press release linked in the comments below. #ADCs #oncology #drugdevelopment #biotech

Synaffix BV today announces it has entered into a licensing agreement with Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The agreement allows Elevation access to Synaffix's clinical stage, site-specific #ADC technology platform, including GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, as well as the toxSYN® linker-payload, SYNstatin E™, for the development of its new HER3 ADC program, EO-1022. Synaffix is eligible to receive up to $368 million in upfront and clinical, regulatory and commercial milestone payments, plus tiered royalties on net sales. For more information, see the full press release linked in the comments below. #ADCs #oncology #drugdevelopment #biotech

Synaffix BV today announces it has entered into a licensing agreement with Illumina, a global leader in DNA sequencing and array-based technologies.   The agreement grants #Illumina access to Synaffix's patented metal-free click chemistry, for next-generation DNA sequencing applications.   For more information, please see the full press release linked in the comments below.   #drugdevelopment #NGS #metalfreeclickchemistry #DNA